TY - JOUR
T1 - Prospective evaluation of lipid management following acute coronary syndrome in non-Western countries
AU - Navar, Ann Marie
AU - Matskeplishvili, Simon T.
AU - Urina-Triana, Miguel
AU - Arafah, Mohammed
AU - Chen, Jaw Wen
AU - Sukonthasarn, Apichard
AU - Corp dit Genti, Valérie
AU - Daclin, Véronique
AU - Peterson, Eric D.
N1 - Funding Information:
The authors would like to thank the registry participants, registry staff, and investigators for their participation. Statistical analyses were managed by Gregory Bigot, from IVIDATA Life Sciences, Paris, France, and Morgane Guennec, statistical lead at IQVIA, Paris, France. Coordination of the development of this manuscript was provided by Pierre Evenou, PhD, from Sanofi. Professional medical writing and editorial assistance was provided by Jane Juif, MSc, and Nicole Scullion, MRes, from HealthCare21 Communications Ltd, Macclesfield, Cheshire, United Kingdom, a Lucid Group agency, and was funded by Sanofi. This trial was sponsored by Sanofi. Medical writing support was funded by Sanofi.
Funding Information:
The authors would like to thank the registry participants, registry staff, and investigators for their participation. Statistical analyses were managed by Gregory Bigot, from IVIDATA Life Sciences, Paris, France, and Morgane Guennec, statistical lead at IQVIA, Paris, France. Coordination of the development of this manuscript was provided by Pierre Evenou, PhD, from Sanofi. Professional medical writing and editorial assistance was provided by Jane Juif, MSc, and Nicole Scullion, MRes, from HealthCare21 Communications Ltd, Macclesfield, Cheshire, United Kingdom, a Lucid Group agency, and was funded by Sanofi. This trial was sponsored by Sanofi. Medical writing support was funded by Sanofi.
Publisher Copyright:
© 2021 The Authors. Clinical Cardiology published by Wiley Periodicals LLC.
PY - 2021/7
Y1 - 2021/7
N2 - Background: Half the global burden of cardiovascular disease (CVD) is concentrated in the Asia-Pacific (APAC) region. Hypothesis: Suboptimal control of low-density lipoprotein cholesterol (LDL-C) may play a large role in the burden of CVD in APAC and non-Western countries. Methods: The Acute Coronary Syndrome Management (ACOSYM) registry is a multinational, multicenter, prospective observational registry designed to evaluate LDL-C control in patients within 6 months after hospitalization following an acute coronary syndrome (ACS) event across nine countries. Results: Overall, 1581 patients were enrolled, of whom 1567 patients met the eligibility criteria; 80.3% of the eligible patients were men, 46.1% had ST-elevation myocardial infarction, and 39.5% had non-ST-elevation myocardial infarction. Most (1245; 79.5%) patients were discharged on a high-intensity statin. During the follow-up, only 992 (63.3%) patients had at least one LDL-C measurement; of these, 52.9% had persistently elevated LDL-C (>70 mg/dl). The patients not discharged on a high-dose statin were more likely (OR 3.2; 95% CI 2.1–4.8) to have an LDL-C above the 70 mg/dl LDL-C target compared with those who were discharged on a high-dose statin. Conclusion: Our real-world registry found that a third or more of post-ACS patients did not have a repeat LDL-C follow-up measurement. In those with an LDL-C follow-up measurement, more than half (52.9%) were not achieving a <70 mg/dl LDL-C goal, despite a greater uptake of high-intensity statin therapy than has been observed in recent evidence. This demonstrates the opportunity to improve post-ACS lipid management in global community practice.
AB - Background: Half the global burden of cardiovascular disease (CVD) is concentrated in the Asia-Pacific (APAC) region. Hypothesis: Suboptimal control of low-density lipoprotein cholesterol (LDL-C) may play a large role in the burden of CVD in APAC and non-Western countries. Methods: The Acute Coronary Syndrome Management (ACOSYM) registry is a multinational, multicenter, prospective observational registry designed to evaluate LDL-C control in patients within 6 months after hospitalization following an acute coronary syndrome (ACS) event across nine countries. Results: Overall, 1581 patients were enrolled, of whom 1567 patients met the eligibility criteria; 80.3% of the eligible patients were men, 46.1% had ST-elevation myocardial infarction, and 39.5% had non-ST-elevation myocardial infarction. Most (1245; 79.5%) patients were discharged on a high-intensity statin. During the follow-up, only 992 (63.3%) patients had at least one LDL-C measurement; of these, 52.9% had persistently elevated LDL-C (>70 mg/dl). The patients not discharged on a high-dose statin were more likely (OR 3.2; 95% CI 2.1–4.8) to have an LDL-C above the 70 mg/dl LDL-C target compared with those who were discharged on a high-dose statin. Conclusion: Our real-world registry found that a third or more of post-ACS patients did not have a repeat LDL-C follow-up measurement. In those with an LDL-C follow-up measurement, more than half (52.9%) were not achieving a <70 mg/dl LDL-C goal, despite a greater uptake of high-intensity statin therapy than has been observed in recent evidence. This demonstrates the opportunity to improve post-ACS lipid management in global community practice.
KW - acute coronary syndrome
KW - lipid management
KW - low-density lipoprotein cholesterol
KW - non-Western countries
KW - statin therapy
UR - http://www.scopus.com/inward/record.url?scp=85107194843&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85107194843&partnerID=8YFLogxK
U2 - 10.1002/clc.23623
DO - 10.1002/clc.23623
M3 - Article
C2 - 34089263
AN - SCOPUS:85107194843
SN - 0160-9289
VL - 44
SP - 955
EP - 962
JO - Clinical Cardiology
JF - Clinical Cardiology
IS - 7
ER -